title: A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
abstract: OBJECTIVE
  To determine the response rate, progression-free survival and toxicity associated with weekly topotecan administered to patients with platinum-sensitive recurrent epithelial ovarian (EOC) in the third-line setting.
  
  
  METHODS
  Patients with measurable platinum-sensitive EOC following failure of second-line chemotherapy were eligible for this phase II study. All patients were initially treated with cytoreductive surgery and platinum/paclitaxel-based chemotherapy. Continuous, weekly topotecan was administered at a starting dose of 4 mg/m(2). Toxicity and efficacy were assessed at various time points after initiation of therapy.
  
  
  RESULTS
  Twenty nine patients were enrolled in this prospective study. Toxicity was acceptable with grade 1/2 nausea being the most commonly experienced side effect (52%). Nine patients (31%) had grade 3/4 leukopenia; however, only 3 patients had febrile neutropenia. Thirteen patients had a treatment delay and six required dose reductions. Twenty two patients were evaluable for efficacy. The overall response rate for weekly topotecan was 13.6% [95% CI; -0.7-27.9%] with 1 complete response, and 2 partial responses. Twelve patients (54.5%), including 2 with minor responses, had stable disease for a median duration of 18 weeks.
  
  
  CONCLUSIONS
  Weekly topotecan at the current schedule in the third-line setting in patients with platinum-sensitive recurrent EOC has modest clinical activity. Toxicity associated with this regimen is acceptable but growth factor support, dose reductions, or schedule alterations may need to be considered in many of these patients.
authors.affiliation: Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of Alabama at Birmingham, AL 35294, USA.
authors.forename: Whitney A
authors.initials: WA
authors.lastname: Spannuth
authors.forename: Charles A
authors.initials: CA
authors.lastname: Leath
authors.forename: Warner K
authors.initials: WK
authors.lastname: Huh
authors.forename: Mack N
authors.initials: MN
authors.lastname: Barnes
authors.forename: Susan A
authors.initials: SA
authors.lastname: Davidson
authors.forename: Larry C
authors.initials: LC
authors.lastname: Kilgore
authors.forename: Edward E
authors.initials: EE
authors.lastname: Partridge
authors.forename: J Maxwell
authors.initials: JM
authors.lastname: Austin
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000494:pharmacology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019772:Topotecan / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D019772:Topotecan